Mechanisms of Antiepileptic Drug Action

The Treatment of Epilepsy: Third Edition

Volumn , Issue , 2009, Pages 91-108

  Walker, Matthew C ^a   Surges, Rainer ^a   Fisher, Andrew ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiepileptic drug action mechanisms; GABA and GABA receptors; GABA uptake and breakdown; Glutamate and glutamate receptors; Intracellular signalling pathways; NMDA receptors associated with channels; Synaptic vesicle protein SV2A

Indexed keywords

EID: 84856502656     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316667.ch7     Document Type: Chapter

References (157)

1. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 2000; 26:13-25.
2. Kuo CC. A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. Mol Pharmacol 1998; 54: 712-721.
3. Yarov-Yarovoy V, Brown J, Sharp EM, Clare JJ, Scheuer T, Catterall WA. Molecular determinants of voltage-dependent gating and binding of pore-blocking drugs in transmembrane segment IIIS6 of the Na(+) channel alpha subunit. J Biol Chem 2001; 276: 20-27.
4. Kuo CC, Chen RS, Lu L, Chen RC. Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications. Mol Pharmacol 1997; 51: 1077-1083.
5. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995; 36(Suppl. 2): S2-12.
6. Segal MM, Douglas AF. Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J Neurophysiol 1997; 77: 3021-3034.
7. Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005; 102: 5507-5512.
8. Reckziegel G, Beck H, Schramm J, Urban BW, Elger CE. Carbamazepine effects on Na+ currents in human dentate granule cells from epileptogenic tissue. Epilepsia 1999; 40: 401-407.
9. Loscher W and Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002; 301:7-14.
10. McLean MJ, Schmutz M, Wamil AW, Olpe HR, Portet C, Feldmann KF. Oxcarbazepine: mechanisms of action. Epilepsia 1994; 35(Suppl. 3):S5-S9.
11. Bonifácio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-da-Silva P. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 2001; 42: 600-608.
12. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 237: 1001-1011.
13. McLean MJ, Bukhari AA, Wamil AW. Effects of topiramate on sodiumdependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 2000; 41(Suppl. 1): S21-S24.
14. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987; 413: 185-188.
15. McLean MJ, Schmutz M, Pozza MF, Wamil A. The influence of rufinamide on sodium currents and action potential firing in rodent neurons. Epilepsia 2005; 46(Suppl. 6): 375.
16. Errington AC, Stöhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltagegated sodium channels. Mol Pharmacol 2008; 73: 157-169.
17. Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Ann Rev Cell Dev Biol 2000; 16: 521-555.
18. van Luijtelaar EL, Ates N, Coenen AM. Role of L-type calcium channel modulation in nonconvulsive epilepsy in rats. Epilepsia 1995; 36:86-92.
19. Hassan H, Grecksch G, Ruthrich H, Krug M. Effects of nicardipine, an antagonist of L-type voltage-dependent calcium channels, on kindling development, kindling-induced learning deficits and hippocampal potentiation phenomena. Neuropharmacology 1999; 38: 1841-1850.
20. Ambrosio AF, Silva AP, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM. Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology 1999; 38: 1349-1359.
21. Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of highvoltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000; 41(Suppl. 1): S52-S60.
22. Gross RA, Macdonald RL. Barbiturates and nifedipine have different and selective effects on calcium currents of mouse DRG neurons in culture: a possible basis for differing clinical actions. The 1987 S. Weir Mitchell award. Neurology 1988; 38: 443-451.
23. Stefani A, Spadoni F, Siniscalchi A, Bernardi G. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol 1996; 307: 113-116.
24. Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport 1996; 7: 3037-3040.
25. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43: 9-18.
26. Pisani A, Bonsi P, Martella G, et al. Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 2004; 45: 719-728.
27. Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR. Oxcarbazepine:preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 1994; 35(Suppl. 5): S47-S50.
28. Stefani A, Pisani A, De Murtas M, et al. Action of GP 47779: the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 1995; 36:997-1002.
29. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel α2δ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007; 28: 75-82.
30. Alden KJ, Garcia J. Differential effect of gabapentin on neuronal and muscle calcium currents. J Pharmacol Exp Ther 2001; 297: 727-735.
31. McCormick DA, Contreras D. On the cellular and network basis of epileptic seizures. Ann Rev Physiol 2001; 63: 815-846.
32. Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 1989; 25: 582-593.
33. Leresche N, Parri HR, Erdemli G, et al. On the action of the antiabsence drug ethosuximide in the rat and cat thalamus. J Neurosci 1998; 18: 4842-4853.
34. Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E. Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol 2001; 60: 1121-1132.
35. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992; 12: 21-27.
36. Todorovic SM, Lingle CJ. Pharmacological properties of T-type Ca2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents. J Neurophysiol 1998; 79: 240-252.
37. Avery RB, Johnston D. Multiple channel types contribute to the lowvoltage-activated calcium current in hippocampal CA3 pyramidal neurons. J Neurosci 1996; 16: 5567-5582.
38. Su H, Sochivko D, Becker A, et al. Up-regulation of a T-type Ca2+ channel causes a long-lasting modification of neuronal firing mode after status epilepticus. J Neurosci 2002; 22: 3645-3655.
39. Löscher W. Anticonvulsant and biochemical effects of inhibitors of GABA aminotransferase and valproic acid during subchronic treatment in mice. Biochem Pharmacol 1982; 31: 837-842.
40. Brooks KA, Shumate MD, Jin H, Rikhter TY, Coulter DA. Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy. Nat Med 1998; 4: 1166-1172.
41. Rivera C, Voipio J, Payne JA, et al. The K+/Cl-co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature 1999; 397: 251-255.
42. Smirnov S, Paalasmaa P, Uusisaari M, Voipio J, Kaila K. Pharmacological isolation of the synaptic and nonsynaptic components of the GABAmediated biphasic response in rat CA1 hippocampal pyramidal cells. J Neurosci 1999; 19: 9252-9260.
43. Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 2002; 42: 210-220.
44. Mehta AK, Ticku MK. An update on GABAA receptors. Brain Res Rev 1999; 29: 196-217.
45. McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 2000; 3: 587-592.
46. Crestani F, Martin JR, Mohler H, Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 2000; 131:1251-1254.
47. Study RE, Barker JL. Diazepam and (-)-pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of gammaaminobutyric acid responses in cultured central neurons. Proc Natl Acad Sci USA 1981; 78: 7180-7184.
48. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989; 25: 213-220.
49. Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia 2006; 47: 704-716.
50. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000; 41(Suppl. 1):S17-S20.
51. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002; 136:659-672.
52. Palma E, Ragozzino D, Di Angelantonio S, et al. The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. Epilepsia 2007; 48: 1842-1849.
53. Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. Epilepsia 2001; 42: 337-344.
54. Monaghan EP, Navalta LA, Shum L, Ashbrook DW, Lee DA. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 1997; 38: 1026-1031.
55. Huguenard JR. Neuronal circuitry of thalamocortical epilepsy and mechanisms of antiabsence drug action. Adv Neurol 1999; 79:991-999.
56. Browne SH, Kang J, Akk G, et al. Kinetic and pharmacological properties of GABAA receptors in single thalamic neurons and GABAA subunit expression. J Neurophysiol 2001; 86: 2312-2322.
57. Snead OCI. Ganaxolone, a selective high-affinity steroid modulator of the alpha-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann Neurol 1998; 44: 688-691.
58. Scanziani M. GABA spillover activates postsynaptic GABA(B) receptors to control rhythmic hippocampal activity. Neuron 2000; 25: 673-681.
59. Vergnes M, Boehrer A, Simler S, Bernasconi R, Marescaux C. Opposite effects of GABAB receptor antagonists on absences and convulsive seizures. Eur J Pharmacol 1997; 332: 245-255.
60. Gale K, Iadarola MJ. Seizure protection and increased nerve-terminal GABA: delayed effects of GABA transaminase inhibition. Science 1980; 208: 288-291.
61. Jolkkonen J, Mazurkiewicz M, Lahtinen H, Riekkinen P. Acute effects of gamma-vinyl GABA on the GABAergic system in rats as studied by microdialysis. Eur J Pharmacol 1992; 229: 269-272.
62. Borden LA. GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int 1996; 29: 335-336.
63. Croucher MJ, Meldrum BS, Krogsgaard-Larsen P. Anticonvulsant activity of GABA uptake inhibitors and their prodrugs following central or systemic administration. Eur J Pharmacol 1983; 89: 217-228.
64. Borden LA, Murali DT, Smith KE, Weinshank RL, Branchek TA, Gluchowski C. Tiagabine, SK & F 89976-A, CI-966: and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994; 269: 219-224.
65. Braestrup C, Nielsen EB, Sonnewald U, et al. R-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier. J Neurochem 1990; 54:639-647.
66. Dalby NO. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 2000; 39:2399-2407.
67. Richards DA, Bowery NG. Comparative effects of the GABA uptake inhibitors, tiagabine and NNC-711: on extracellular GABA levels in the rat ventrolateral thalamus. Neurochem Res 1996; 21:135-140.
68. Sills GJ, Patsalos PN, Butler E, Forrest G, Ratnaraj N, Brodie MJ. Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina. Neurology 2001; 57: 196-200.
69. Semyanov A, Walker MC, Kullmann DM, Silver RA. Tonically active GABAA receptors: modulating gain and maintaining the tone. Trends Neurosci 2004; 27: 262-269.
70. Overstreet LS, Westbrook GL. Paradoxical reduction of synaptic inhibition by vigabatrin. J Neurophysiol 2001; 86: 596-603.
71. Draguhn A, Heinemann U. Different mechanisms regulate IPSC kinetics in early postnatal and juvenile hippocampal granule cells. J Neurophysiol 1996; 76: 3983-3993.
72. Nusser Z, Naylor D, Mody I. Synapse-specific contribution of the variation of transmitter concentration to the decay of inhibitory postsynaptic currents. Biophys J 2001; 80: 1251-1261.
73. Isaacson JS, Solis JM, Nicoll RA. Local and diffuse synaptic actions of GABA in the hippocampus. Neuron 1993; 10: 165-175.
74. Thompson SM, Gahwiler BH. Effects of the GABA uptake inhibitor tiagabine on inhibitory synaptic potentials in rat hippocampal slice cultures. J Neurophysiol 1992; 67: 1698-1701.
75. Otis TS, Mody I. Differential activation of GABAA and GABAB receptors by spontaneously released transmitter. J Neurophysiol 1992; 67:227-235.
76. Sutch RJ, Davies CC, Bowery NG. GABA release and uptake measured in crude synaptosomes from Genetic Absence Epilepsy Rats from Strasbourg (GAERS). Neurochem Int 1999; 34: 415-425.
77. Coenen AM, Blezer EH, van Luijtelaar EL. Effects of the GABA-uptake inhibitor tiagabine on electroencephalogram, spike-wave discharges and behaviour of rats. Epilepsy Res 1995; 21: 89-94.
78. Jackson MF, Esplin B, Capek R. Activity-dependent enhancement of hyperpolarizing and depolarizing gamma-aminobutyric acid (GABA) synaptic responses following inhibition of GABA uptake by tiagabine. Epilepsy Res 1999; 37: 25-36.
79. Hassel B, Johannessen CU, Sonnewald U, Fonnum F. Quantification of the GABA shunt and the importance of the GABA shunt versus the 2-oxoglutarate dehydrogenase pathway in GABAergic neurons. J Neurochem 1998; 71: 1511-1518.
80. McGeer PL, Eccles JC, McGeer EG, eds. Molecular Neurobiology of the Mammalian Brain, 2nd edn. New York: Plenum Press, 1987; 175-96.
81. Hollman M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994; 17: 31-108.
82. Patneau DK, Mayer ML. Structure-activity relationships for amino acid transmitter candidates acting at the N-methyl-d-aspartate and quisqualate receptors. J Neurosci 1990; 10: 2385-2399.
83. Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000; 41(Suppl. 1):S10-S16.
84. Carunchio I, Pieri M, Ciotti MT, Albo F, Zona C. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia 2007; 48: 654-662.
85. Chappell AS, Sander JW, Brodie MJ, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 2002; 58: 1680-1682.
86. Kullmann DM. Presynaptic kainate receptors in the hippocampus:slowly emerging from obscurity. Neuron 2001; 32: 561-564.
87. Semyanov A, Kullmann DM. Kainate receptor-dependent axonal depolarization and action potential initiation in interneurons. Nat Neurosci 2001; 4: 718-723.
88. Ben Ari Y, Cossart R. Kainate, a double agent that generates seizures:two decades of progress. Trends Neurosci 2000; 23: 580-587.
89. Smolders I, Bortolotto ZA, Clarke VR, et al. Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nat Neurosci 2002; 5: 796-804.
90. Khalilov I, Hirsch J, Cossart R, Ben Ari Y. Paradoxical anti-epileptic effects of a GluR5 agonist of kainate receptors. J Neurophysiol 2002; 88: 523-527.
91. Edmonds B, Gibb AJ, Colquhoun D. Mechanisms of action of glutamate receptors and the time course of excitatory synaptic currents. Annu Rev Physiol 1995; 57: 495-579.
92. White HS, Harmsworth WL, Sofia RD, Wolf HH. Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res 1995; 20:41-48.
93. Subramaniam S, Donevan SD, Rogawski MA. Block of the N-methyld-aspartate receptor by remacemide and its des-glycine metabolite. J Pharmacol Exp Ther 1996; 276: 161-168.
94. Rusakov DA, Kullmann DM. Extrasynaptic glutamate diffusion in the hippocampus: ultrastructural constraints, uptake, and receptor activation. J Neurosci 1998; 18: 3158-3170.
95. Chapman AG, Nanan K, Williams M, Meldrum BS. Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology 2000; 39: 1567-1574.
96. Abdul-Ghani AS, Attwell PJ, Singh KN, Bradford HF, Croucher MJ, Jane DE. Anti-epileptogenic and anticonvulsant activity of L-2-amino-4-phosphonobutyrate, a presynaptic glutamate receptor agonist. Brain Res 1997; 755: 202-212.
97. Attwell PJ, Singh KN, Jane DE, Croucher MJ, Bradford HF. Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S, 2'R, 3'R)-2-(2', 3'-dicarboxycyclopropyl)glycine (DCG-IV). Brain Res 1998; 805:138-143.
98. Chapman AG, Talebi A, Yip PK, Meldrum BS. Anticonvulsant activity of a mGlu(4alpha) receptor selective agonist (1S, 3R, 4S)-1-aminocyclopentane-1: 2: 4-tricarboxylic acid. Eur J Pharmacol 2001; 424: 107-113.
99. Moldrich RX, Jeffrey M, Talebi A, Beart PM, Chapman AG, Meldrum BS. Anti-epileptic activity of group II metabotropic glutamate receptor agonists (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268) and (-)-2-thia-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY389795). Neuropharmacology 2001; 41: 8-18.
100. Nobile M, Lagostena L. A discriminant block among K+ channel types by phenytoin in neuroblastoma cells. Br J Pharmacol 1998; 124:1698-1702.
101. Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003; 45: 661-671.
102. Freiman TM, Kukolja J, Heinemeyer J, et al. Modulation of K+-evoked [3H]-noradrenaline release from rat and human brain slices by gabapentin:involvement of KATP channels. Naunyn Schmiedebergs Arch Pharmacol 2001; 363: 537-542.
103. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000; 58: 253-262.
104. Bender RA, Soleymani SV, Brewster AL, et al. Enhanced expression of a specific hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN) in surviving dentate gyrus granule cells of human and experimental epileptic hippocampus. J Neurosci 2003; 23: 6826-6836.
105. Budde T, Caputi L, Kanyshkova T, et al. Impaired regulation of thalamic pacemaker channels through an imbalance of subunit expression in absence epilepsy. J Neurosci 2005; 25: 9871-9882.
106. Munsch T, Pape HC. Up-regulation of the hyperpolarization activated cation current in rat thalamic relay neurones by acetazolamide. J Physiol 1999; 519: 505-514.
107. Poolos NP, Migliore M, Johnston D. Pharmacological up-regulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 2002; 5: 767-774.
108. Surges R, Freiman TM, Feuerstein TJ. Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells. Epilepsia 2003; 44: 150-156.
109. Wan X, Mathers DA, Puil E. Pentobarbital modulates intrinsic and GABA-receptor conductances in thalamocortical inhibition. Neuroscience 2003; 121: 947-958.
110. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004; 101: 9861-9866.
111. Kaminski RM, Matagne A, Leclercq K, et al. SV2A protein is a broadspectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008; 54: 715-720.
112. Naffah-Mazzacoratti MG, Amado D, Cukiert A, et al. Monoamines and their metabolites in cerebrospinal fluid and temporal cortex of epileptic patients. Epilepsy Res 1996; 25: 133-137.
113. Corcoran ME. Characteristics of accelerated kindling after depletion of noradrenaline in adult rats. Neuropharmacology 1988; 27:1081-1084.
114. Shouse MN, Langer J, Bier MJ, et al. The alpha 2-adrenergic agonist clonidine suppresses seizures whereas the alpha 2-adrenergic antagonist idazoxan promotes seizures in amygdala-kindled kittens: a comparison of amygdala and pontine microinfusion effects. Epilepsia 1996; 37:709-717.
115. Bjorkland A and Lindvall O. Grafts of locus coeruleus in rat amygdalapiriform cortex suppress seizure development in hippocampal kindling. Exp Neurol 1989; 106: 125-132.
116. Dailey JW, Reith ME, Yan QS, Li MY, Jobe PC. Carbamazepine increases extracellular serotonin: lack of antagonism by tetrodotoxin or zero Ca2+. Eur J Pharm 1997; 328: 153-162.
117. Starr MS. The role of dopamine in epilepsy. Synapse 1996; 22:159-194.
118. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995; 376:572-575.
119. Thierry AM, LeDouarin C, Penit J, Ferron A, Glowinski J. Variation in the ability of neuroleptics to block the inhibitory influence of dopaminergic neurons on the activity of cells in the rat prefrontal cortex. Brain Res Bull 1986; 16: 155-160.
120. Zhou F-M, Hablitz JJ. Dopamine modulation of membrane and synaptic properties of interneurons in rat cerebral cortex. J Neurophysiol 1999; 81: 967-976.
121. McIntyre DC, Edson N. Kindling-based status epilepticus: effect of norepinephrine depletion with 6-hydroxydopamine. Exp Neurol 1989; 77: 700-704.
122. Libet B, Gleason CA, Wright EW, Feinstein B. Suppression of an epileptiform type of electrocortical activity in the rat by stimulation in the vicinity of the locus coeruleus. Epilepsia 1977; 18: 451-462.
123. Olpe HR, Jones RS. The action of anticonvulsant drugs on the firing of locus coeruleus neurons: selective, activating effect of carbamazepine. Eur J Pharmacol 1983; 91: 107-110.
124. Baf MH, Subhash NM, Lakshmane KM, Roa BS. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem Int 1994; 24: 67-72.
125. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46: 157-203.
126. Moore RY, Halaris AE. Hippocampal innervation by serotonin neurons of the midbrain raphe in the rat. J Comp Neurol 1975; 164:171-184.
127. Schmitz D, Empson RM, Heinemann U. Serotonin reduces inhibition via 5HT1A receptors in area CA1 of rat hippocampal slices in vitro. J Neurosci 1995; 15: 7217-7225.
128. Ropert N, Guy N. Serotonin facilitates gabaergic transmission in the CA1 region of rat hippocampus in vitro. J Physiol 1991; 441:121-136.
129. Wada Y, Nakamura M, Hasegawa H, Yamaguchi N. Role of serotonin receptor subtype in seizures kindled from the feline hippocampus. Neurosci Lett 1992; 141: 21-24.
130. Lazarova M, Bendotti C, Samanin R. Studies on the role of serotonin in different regions of the rat central nervous system on pentlyenetetrazole-induced seizures and the effect of di-n-propylacetate. Naunyn-Schmiedebergs Arch Pharmacol 1983; 322: 147-152.
131. Jobe PC, Picchioni AL, Chin L. Role of brain 5-hydroxytryptamine in audiogenic seizures in the rat. Life Sci 1973; 13: 1-13.
132. Dailey JW, Mishra PK, Ko KH, Penny JE, Jobe PC. Serotonergic abnormalities in the central nervous system of seizure-naive genetically epilepsy-prone rats. Life Sci 1992; 50: 319-326.
133. Biggs CS, Pearce BR, Fowler LJ, Whitton PS. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 1992; 59: 1702-1708.
134. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ dependent dopamine release. Epilepsy Res 1992; 13: 113-119.
135. Southam E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharm 1998; 358: 19-24.
136. McLean M, MacDonald RL. Carbamazepine and 10,11 epoxycarbamazepine produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 238: 727-738.
137. Rock DM, MacDonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810: CI 912) a novel anticonvulsant. Epilepsy Res 1989; 3:138-143.
138. Van den Berg RJ, Kok P, Voskuyl RA. Valproate and sodium currents in cultured hippocampal neurons. Exp Brain Res 1993; 93:279-287.
139. Okada M, Kawata Y, Kiryu K, et al. Effects of non-toxic and toxic concentrations on phenytoin on monoamines levels in rat brain. Epilepsy Res 1997; 28: 155-163.
140. Okada M, Kawata Y, Mizuno K, et al. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998; 124:1277-1285.
141. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995; 22: 193-205.
142. Okada M, Hirano T, Mizuno K, et al. Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus. Epilepsy Res 1997; 28: 143-153.
143. Dailey JW, Reith ME, Steidley KR, Milbrandt JC, Jobe PC. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia 1998; 39: 1054-1063.
144. Nagamoto I, Akasaki Y, Uchida M, et al. Effects of combined administration of zonisamide and valproic acid or phenytoin to nitric oxide production, monoamines and zonisamide concentrations in the brain of seizure-susceptible EL mice. Brain Res Bull 2000; 52: 211-218.
145. Kimura M, Tanaka N, Kimura Y, Miyake K, Kitaura T, Fukuchi H. Pharmacokinetic interaction of zonisamide in rats. Effect of zonisamide on other antiepileptics. Biol Pharm Bull 1993; 16: 722-725.
146. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004; 10:685-692.
147. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276:36734-36741.
148. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72: 1327-1330.
149. Hao Y, Creson T, Zhang L, et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci 2004; 24: 6590-6599.
150. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417:292-295.
151. Pal S, Sun D, Limbrick D, Rafiq A, DeLorenzo RJ. Epileptogenesis induces long-term alterations in intracellular calcium release and sequestration mechanisms in the hippocampal neuronal culture model of epilepsy. Cell Calcium 2001; 30: 285-296.
152. Bardo S, Cavazzini MG, Emptage N. The role of the endoplasmic reticulum Ca2+ store in the plasticity of central neurons. Trends Pharmacol Sci 2006; 27: 78-84.
153. Cataldi M, Lariccia V, Secondo A, di Renzo G, Annunziato L. The antiepileptic drug levetiracetam decreases the inositol 1,4,5-trisphosphate-dependent [Ca2+]I increase induced by ATP and bradykinin in PC12 cells. J Pharmacol Exp Ther 2005; 313: 720-730.
154. Okada M, Yoshida S, Zhu G, Hirose S, Kaneko S. Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems. Neuroscience 2005; 134:233-246.
155. Yoshida S, Okada M, Zhu G, Kaneko S. Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors. Epilepsy Res 2005; 67: 153-162.
156. Yoshida S, Okada M, Zhu G, Kaneko S. Carbamazepine prevents breakdown of neurotransmitter release induced by hyperactivation of ryanodine receptor. Neuropharmacology 2007; 52: 1538-1546.
157. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41(Suppl. 1): S3-S9.